



## Selective Antitumor Therapy Based on Nanotechnology

Guest Editors:

**Dr. Rosario M. Sanchez-Martin**

GENYO, Centre for Genomics and  
Oncological Research:  
Pfizer/University of  
Granada/Andalusian Regional  
Government, 18016 Granada,  
Spain

**Dr. Victoria Cano-Cortés**

GENYO Researcher Centre,  
University of Granada, Granada,  
Spain

Deadline for manuscript  
submissions:

**closed (15 September 2022)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue aims to publish original research articles and reviews focusing on the latest developments in nanotechnology-based targeted antitumor therapy. This Special Issue welcomes research findings that help to improve cancer therapy by applying strategies based on nanoparticles, such as polymeric nanoparticles, inorganic nanoparticles, liposomes, dendrimers, exosomes, etc.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: targeted drug delivery, theranostics, DNA nanotechnology, nanovectors, gene delivery, gene editing, strategies to overcome drug resistance, immunotherapy, tumor models to validate nanoformulations, the mechanisms of action of nanodevices, nanotoxicology, the preclinical characterization of nanodevices, bio-inspired nanomaterials, exosomes for cancer therapy, etc.

We look forward to receiving your contributions.

Dr. Rosario M. Sanchez-Martin

Dr. Victoria Cano-Cortés

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma